Position of the Transparency Council – Inovelon (rufinamide)

At its meeting on 08 August 2022 the Transparency Council adopted Position No. 73/2022 on the legitimacy of granting consent for reimbursement of Inovelon (Rufinamide) for the indications: drug-resistant epilepsy; Lennox-Gastaut syndrome; West syndrome; Rasmussen syndrome.

Publication in Public Information Bulletin (BIP)